Hyalouronic Acid and Periodontal Surgery
Healing Effect of Hyaluronic Acid Gel in Conjunction With Periodontal Surgery. A Randomized Controlled Clinical and Biomarkers Study
This study investigated the effectiveness of hyaluronic acid gel in enhancing soft tissue healing after periodontal surgery for residual pockets (5-8 mm). A 3-month prospective, randomized controlled trial included 26 patients from Aristotle University's Postgraduate Periodontology Clinic who had completed initial periodontal therapy and exhibited at least one residual pocket.
Participants were randomly assigned to an experimental group (receiving 0.6 ml hyaDENT BG hyaluronic acid gel) or a control group (receiving 0.6 ml saline). Before surgery, gingival crevicular fluid (GCF) samples were collected for inflammatory and healing biomarkers (PGE-2, MMP-9, IL-1β, VEGF, EGF), analyzed using ELISA. Surgery was performed at sites with persistent pockets, and follow-ups occurred at 14 days and 3 months postoperatively.
Healing was assessed using the Landry, Turnbull, and Howley Wound Healing Index (WHI). Clinical parameters, including probing pocket depth (PPD), bleeding on probing (BoP), clinical attachment level (CAL), and plaque index (PI), were measured at 3 months, with treatment success defined as PPD ≤4 mm without BoP. Patient-reported outcomes, such as pain, swelling, chewing, speech, and aesthetics, were evaluated using a Visual Analog Scale (VAS).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The current study aimed to investigate the effectiveness of hyaluronic acid gel in accelerating soft tissue healing following periodontal surgery for the treatment of residual periodontal pockets with a depth of 5-8 millimeters.
A prospective, randomized controlled clinical study with a duration of 3 months was designed. Twenty six (26) patients attending the Postgraduate Periodontology Clinic of the Dental School at Aristotle University of Thessaloniki (AUTH). These patients had completed Steps 1 and 2 of initial causative periodontal therapy and had at least one residual periodontal pocket with a depth of 5-8 mm during the re-evaluation (according to the 2018 classification of periodontal and peri-implant diseases). Clinical measurements and radiographic evaluation were performed using the parallel technique, and patients received oral hygiene instructions as part of the initial assessment. Surgical intervention was scheduled two weeks later at sites showing a periodontal pocket depth of 5-8 mm during re-evaluation. The participants were randomly assigned to one of two groups: the experimental group, which received surgical treatment with 0.6 ml of hyaDENT BG hyaluronic acid gel inside the flap, and the control group, which received surgical treatment with 0.6 ml of normal saline (placebo). Prior to surgery, two sterile paper strips (Periostrips) were used to collect gingival crevicular fluid (GCF) samples for inflammatory biomarkers (PGE-2, MMPs-9, IL-1β) and markers for angiogenesis and epithelial cell proliferation (VEGF, EGF). Biomarker concentrations were assessed using the Elisa technique. The patients were followed up on the 14th day and at 3 months post-surgery. GCF samples were taken from the same periodontal pocket on the 14th day (after suture removal) for the evaluation of VEGF and EGF, and at 3 months for the study of PGE-2, MMP-9, and IL-1β. Clinical re-assessments were conducted at 3 months, including measurements of pocket depth (PPD), bleeding on probing (BoP), clinical attachment level (CAL), and plaque index (PI). Treatment success was defined as a pocket depth of ≤4 mm without bleeding on probing at the initial lesion sites. Soft tissue healing was evaluated macroscopic using the Landry, Turnbull, and Howley Wound Healing Index (WHI). Postoperative pain, swelling, chewing and speaking ability, and appearance were assessed using a Visual Analog Scale (VAS).
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Central Macedonia
-
Thessaloniki, Central Macedonia, Greece, 54124
- Aristotle University of Thessaloniki, School of Dentistry
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- the presence of at least one residual pocket with depth 5-8mm at the follow - up examination, after the completion of Steps 1 and 2 of the initial etiological periodontal therapy.
Exclusion Criteria:
- severe systematic disease of patients by which a surgical procedure cannot be performed (e.g., uncontrolled diabetes, chemotherapy, immunosuppressive therapy, use of bisphosphonates)
- previous periodontal surgery at the site of the lesion
- antibiotic intake in the last one month before treatment
- patients who smoke more than 10 cigarettes per days
- use drugs or alcohol
- women in pregnancy or lactation period
- periodontal lesions indicated for regeneration (3-walled, craters) were excluded from the study and were threated accordingly
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Periodontal surgery and Hyalouronic acid
Test Group (Group HA): periodontal surgery and application of 0.6 ml of hyaDENT BG hyaluronic acid gel
|
Periodontal surgery and Hyalouronic acid
|
|
Placebo Comparator: Periodontal surgery and saline solution/ placebo
Control group (Group C):periodontal surgery and application of 0.6 ml of saline solution/placebo.
|
Periodontal surgery and saline solution/ placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Periodontal pocket depth - change in millimeters (mm)
Time Frame: Baseline to 3 months
|
Periodontal pockrt depth is measured using a periodontal probe at six sites per tooth.
(Periodontal probe UNC15, Hu-Friedy, Rotterdam, the Netherlands)
|
Baseline to 3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Attachment Level-CAL in millimeters (mm).
Time Frame: Baseline to 3 months
|
Clinical Periodontal Marker: The distance in mm from the CEJ to the gingival margin (Periodontal probe UNC15, Hu-Friedy, Rotterdam, the Netherlands) Time Frame: 6 months
|
Baseline to 3 months
|
|
Bleeding on Probing-BoP - Change in percentage
Time Frame: baseline to 3 months
|
Clinical Periodontal Marker: Bleeding after slight pressure by a standardized (dimensions and shape) periodontal probe with a controlled (∼0.25 N) force to the apical end of the sulcus (Periodontal probe UNC15, Hu-Friedy, Rotterdam, the Netherlands)
|
baseline to 3 months
|
|
Plaque Index-PI - Change in percentage
Time Frame: baseline to 3 months
|
PI : Assessment of plaque accumulation at six sites per tooth.
Percentage of sites with plaque on probing.
|
baseline to 3 months
|
|
Interleukin-1 beta-IL-1β in pg/ml
Time Frame: baseline to 3 months
|
IL-1β: Gingival crevicular fluid levels of Interleukin-1 beta (IL-1β) using perio strips into the gingival sulcus. Unit of Measure: pg/mL |
baseline to 3 months
|
|
Vascular Endothelial Growth Factor-VEGF in pg/ml
Time Frame: 14 days post-treatment
|
VEGF: Gingival crevicular fluid levels of Vascular Endothelial Growth Factor using perio strips into the gingival sulcus. Unit of Measure: pg/mL |
14 days post-treatment
|
|
Early Wound Healing Index by Landry, Turnbull, and Howley in score range 0-5
Time Frame: 14 days post-treatment
|
Early Wound Healing Index Score: Soft tissue healing assessed using the Early Wound Healing Index by Landry, Turnbull, and Howley. Scores range from 0 to 5. Higher scores indicate better healing. Unit of Measure: Score (0 worst-5 better ) |
14 days post-treatment
|
|
Patient-Reported treatment Experience in VAS score
Time Frame: 14 days post-treatment
|
Patient-Reported treatment Experience Overall treatment experience assessed using a Visual Analog Scale (VAS).
Scores range from 1 to 10. Higher scores indicate better patient-reported experience.
Unit of Measure:1(worst)-10(better)
|
14 days post-treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Elpiniki Vlachodimou, MSc, Aristotle University Of Thessaloniki
- Study Director: Aikaterini - Elisavet Doufexi, Assistant Professor, Aristotle University Of Thessaloniki
- Study Director: Ioannis Vouros, Professor, Aristotle University Of Thessaloniki
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 22/27.03.2024
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peridontal Disease
-
NCT06789458Recruiting
-
NCT06808373RecruitingDental Anxiety | Peridontal Disease
-
NCT06700161Completed
-
NCT07243145CompletedPeriodontal Inflammation | Periodontitis, Adult | Peridontal Disease
-
NCT00012688CompletedDiabetes Mellitus | Poor Glycemic Control | Peridontal Disease
-
NCT06882564RecruitingEfficacy of Resveratrol Containing Mouthwash in Reducing Halitosis Related Porphyrymonas Gingivalis.Halitosis | Mouth Disease | Bleeding Gum | Peridontal Disease | Plaque Induced Gingival Disease
-
NCT06764043CompletedPeridontal Disease | Molar-Incisor Hypomineralization
-
NCT06818045CompletedRheumatic Arthritis | Peridontal Disease
Clinical Trials on Hyalouronic Acid
-
NCT01661764CompletedColorectal Adenomatous Polyps
-
NCT02593318CompletedAlzheimer's Disease (AD)
-
NCT07329907CompletedWarts | Human Papilloma Virus (HPV)
-
NCT07325123Not yet recruitingSolid Tumor Malignancies
-
NCT07393438Not yet recruitingMultidrug-Resistant Tuberculosis | MDR-TB | Rifampicin-resistant Tuberculosis | RR-TB
-
NCT02984150Completed
-
NCT07617480Enrolling by invitationDental Bonding | Dental Etching | Acid Etching | Acid Etching, Dental | Dental Acid Etching
-
NCT07604844Not yet recruiting
-
NCT04143295AvailableMct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency